OR WAIT null SECS
The company has introduced Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
Berkeley Lights, a US-based digital cell biology company, announced on April 5, 2021 that it has launched Opto Assure, a series of assays that provide yield and product quality data at an earlier stage in cell-line development.
According to a company press release, the first series supports direct detection of product aggregates for a faster ramp toward volume production by evaluating biotherapeutic protein quality sooner in the antibody therapeutic development process, allowing for customers to rapidly choose clonal cell lines with promising manufacturability profiles.
“We’re excited to empower manufacturers of complex therapeutics, such as bispecifics, to develop better production cell lines faster. As we build out the Opto Assure series, customers can look forward to added capabilities that further reduce resources spent on preventing product failures downstream and ensure a more efficient process,” said John Proctor, PhD, senior vice-president of Antibody Therapeutics at Berkeley Lights, in the press release.
Source: Berkeley Lights